Noxopharm Limited (ASX:NOX)
Australia · Delayed Price · Currency is AUD 0.0650
-0.0020 (-2.99%)
Sep 18, 2026, 1:54 PM AEST
Noxopharm Revenue
In the fiscal year ending June 30, 2026, Noxopharm had annual revenue of 1.43M AUD, down -49.40%. Noxopharm had revenue of -303.50K in the half year ending June 30, 2026.
Revenue
1.43M
Revenue Growth
-49.40%
P/S Ratio
14.42
Revenue / Employee
n/a
Employees
n/a
Market Cap
20.58M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 1.43M | -1.39M | -49.40% |
| Jun 30, 2025 | 2.82M | 420.56K | 17.52% |
| Jun 30, 2024 | 2.40M | -3.61M | -60.06% |
| Jun 30, 2023 | 6.01M | 581.44K | 10.71% |
| Jun 30, 2022 | 5.43M | -179.61K | -3.20% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 46.28M |
| Radiopharm Theranostics | 13.50M |
| Immuron | 7.71M |
| Argenica Therapeutics | 5.48M |
| Neurotech International | 4.73M |
| Proteomics International Laboratories | 3.37M |
| Imugene | 2.09M |
| Nexsen | 1.09M |